People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GT Biopharma, Inc. | — | Biotechnology | Series B | $53.5M | $98.3M | 2025 |
| First Wave BioPharma, Inc. | — | Biotechnology | Series B | $50.4M | $13.4M | 2017 |
| Relmada Therapeutics, Inc. | — | Biotechnology | Series A | $36.1M | $29.9M | 2017 |
| Eton Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $27.6M | $255.0M | 2017 |
| International Stem Cell CORP | — | Biotechnology | Series A | $7.5M | $90.4M | 2012 |
Charles Casamento at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Casamento on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles J Casamento | 2 | 5 |
| Maged Shenouda | 2 | 3 |
| Donald Wright | 1 | 8 |
| David Hoffman | 1 | 7 |
| James Sapirstein | 1 | 7 |
| Paul V. Maier | 1 | 6 |
| Paul Kelly | 1 | 5 |
| Mark L. Baum | 1 | 5 |
| Johan (Thijs) Spoor | 1 | 4 |
| Paul Maier | 1 | 4 |
| Mark Baum | 1 | 4 |
| Johan M Spoor | 1 | 3 |
| Sarah Romano | 1 | 3 |
| Norbert G. Riedel | 1 | 3 |
| Don Wright | 1 | 3 |
| Andrew Ritter | 1 | 3 |
| Sergio Traversa | 1 | 3 |
| Andrew Boll | 1 | 3 |
| Michael Breen | 1 | 3 |
| Anthony Cataldo | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.